

# Maximising treatment benefit for patients with ALK+ NSCLC

14.00–15.30

Friday 26 September 2014

IFEMA Congress Centre

Pamplona Auditorium

Madrid, Spain



## Invitation

Dear Colleague

On behalf of the faculty, I am delighted to invite you to the Pfizer Oncology satellite symposium: 'Maximising treatment benefit for patients with ALK+ NSCLC'. This symposium will take place on **Friday 26 September**, from **14.00 to 15.30**, during the European Society for Medical Oncology (ESMO) congress in Madrid, Spain.

Rapid advances in our understanding of tumour biology mean we are now able to target a variety of molecular alterations with specific therapies. Identification of anaplastic lymphoma kinase (ALK) translocations as an oncogenic driver, and approval of the ALK inhibitor, crizotinib, in Europe for patients with previously treated NSCLC, have revolutionised the testing and treatment of this disease.

During this symposium, we will examine the importance of collaboration within a multidisciplinary clinical team to ensure all patients with ALK+ NSCLC are identified and receive appropriate treatment. Our faculty will discuss the optimal management of patients with ALK+ NSCLC based on a review of the crizotinib clinical trials and their personal clinical experience.

I hope you enjoy what I'm sure will be an informative and engaging symposium.

Tony Mok, Chair

Professor of Clinical Oncology, Li Shu Fun Medical Foundation  
The Chinese University of Hong Kong, Hong Kong

## Programme

- 14.00 Welcome and introduction  
Tony Mok (Hong Kong)
- 14.05 Crizotinib clinical data in ALK+ NSCLC  
Alice Shaw (USA)
- 14.25 The patient's journey:  
A multidisciplinary team approach  
Sanjay Popat (UK)
- 14.40 Panel discussion: ALK+ NSCLC: How to  
ensure no patient is left behind  
All faculty
- 15.00 Sharing clinical experience with  
crizotinib  
Oliver Gautschi (Switzerland)
- 15.15 Panel discussion and close:  
Best practice for challenging clinical  
scenarios  
All faculty